Global Genetic Obesity Drugs Market Overview:
Obesity is a global health concern that has negative consequences for all organ systems, resulting in increased disease and growing healthcare expenses. If criteria are met and more severe intervention is needed, people with obesity who are failing lifestyle therapy should be advanced to appropriate pharmacological treatment modalities, medical devices, and/or bariatric surgery. Obesity is caused by a chronic energy imbalance in which a person consumes more calories from food and drink than their body requires to power its metabolic and physical functions. Obesity has become more common in recent decades, owing to an obesogenic environment that provides easy access to high-calorie meals while limiting possibilities for physical activity. The obesity pandemic might be seen as a communal reaction to this situation. Obesity is a severe public health issue since it raises the risk of diabetes, heart disease, stroke, and other serious illnesses.
- Rise in Unhealthy and Junk Food Lifestyle
- Increasing Diabetes Patients
- High Cost of Obesity Drugs
- Rising Opportunities in Emerging Economies
- Lack of Healthcare Infrastructure in Developing Nations
- High Competition among Established Players
The demand for Genetic Obesity Drugs is increasing. The industry is segmented, but it is predicted to grow as rise in unhealthy lifestyle and increasing investment in R&D, among other factors, drive the market forward. Businesses in this sector face global competition from market leaders who control a large share of the market. Companies are differentiating their products from competition by employing environmentally friendly materials and manufacturing techniques. The Leading Players are engaging in strategic global expansion to maintain their Market Position.
Some of the key players profiled in the report are Pfizer (United States), Sanofi (France), Roche Holding AG (Switzerland), Regeneron Pharmaceuticals (United States), AstraZeneca (United Kingdom), Gilead Sciences (United States), Bristol Myers Squibb (United States), Novo Nordisk (Denmark), Rhythm Pharmaceuticals (United States) and PreveCeutical Medical (Canada). Additionally, following companies can also be profiled that are part of our coverage like EraCal Therapeutics (Switzerland), Phenomix Sciences (United States) and Antag Therapeutics (Denmark). Analyst at AMA Research see United States Players to retain maximum share of Global Genetic Obesity Drugs market by 2026. Considering Market by Type, the sub-segment i.e. Monogenic will boost the Genetic Obesity Drugs market. Considering Market by Category, the sub-segment i.e. Class 1: BMI - 30 to < 35 will boost the Genetic Obesity Drugs market. Considering Market by Drug , the sub-segment i.e. Bupropion-naltrexone will boost the Genetic Obesity Drugs market. Considering Market by Distribution Channel, the sub-segment i.e. Hospitals pharmacy will boost the Genetic Obesity Drugs market. Considering Market by End-User, the sub-segment i.e. Hospitals will boost the Genetic Obesity Drugs market.
Latest Market Insights:
In November 2021 Novo Nordisk had announced the acquisition of Dicerna Pharmaceuticals. The acquisition of Dicerna's ribonucleic acid interference (RNAi) platform is a strategic addition to Novo Nordisk's existing research technology platforms, and it aligns with the company's strategy of using a diverse set of technology platforms that can be applied across all of Novo Nordisk's therapeutic focus areas.
What Can be Explored with the Genetic Obesity Drugs Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Genetic Obesity Drugs Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Genetic Obesity Drugs
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Genetic Obesity Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Genetic Obesity Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture and Capitalist, New entrants/investors, Analysts and Strategic Business Partners, Hospital, Clinics, Diagnostic Centres and End-use industries.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.